← All trials
NCT04906629
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 1, 2021
- Primary completion
- Apr 30, 2022
- Completion date
- Jun 30, 2022
- First posted
- May 28, 2021
- Last posted
- May 28, 2021
- Enrollment
- 50
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of GenevaLead sponsor
- University of GenevaReponsible party - principal investigator
- University of GenoaOverall official - principal investigator
- Inovio PharmaceuticalsCollaborator
- Defense Advanced Research Projects AgencyCollaborator
- Global Urgent and Advanced Research and Development (GuardRX)Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.